The study aimed to explore how intratracheal instillation of nano-TiO(2) affects dyslipidemia and atherosclerosis in apolipoprotein E-knockout mice.
Researchers divided 46 mice into different groups based on their treatment— non-treatment, PBS control, and three dosage levels (high, medium, low)—and administered the substance twice a week for six weeks.
Results indicated that mice in the high-dose group experienced significant weight loss and elevated levels of total cholesterol (TC) and triglycerides (TG) compared to other groups, suggesting that nano-TiO(2) exposure can worsen lipid profiles and potentially promote cardiovascular issues.